BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9602 related articles for article (PubMed ID: 1790139)

  • 1. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
    Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
    J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.
    Azogui O; Avril MF; Margulis A; Guillard M; Caillou B; Prade M
    J Invest Dermatol; 1991 Sep; 97(3):425-9. PubMed ID: 1831465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
    Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
    J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.
    Steger GG; Gnant MF; Djavanmard MP; Mader RM; Jakesz R; Pierce W; deKernion JB; Figlin R; Belldegrun A
    J Cancer Res Clin Oncol; 1997; 123(6):317-24. PubMed ID: 9222297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes.
    Chakraborty NG; Sporn JR; Pasquale DR; Ergin MT; Mukherji B
    Clin Immunol Immunopathol; 1991 Jun; 59(3):407-16. PubMed ID: 2029793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
    Koo AS; Tso CL; Shimabukuro T; Peyret C; deKernion JB; Belldegrun A
    J Immunother (1991); 1991 Oct; 10(5):347-54. PubMed ID: 1790142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
    Salmeron MA; Morita T; Seki H; Platsoucas CD; Itoh K
    Cancer Immunol Immunother; 1992; 35(3):211-7. PubMed ID: 1386286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 481.